Pharnext to Present at 4th International Neurotech Investing and Partnering Conference
Pharnext SA (FR00111911287 - ALPHA) (Paris:ALPHA) , a biopharmaceutical company pioneering a new approach to the development of innovative drugs based on the combination and repositioning of known drugs, today announced that company management will present a corporate overview at the 4th International Neurotech Investing and Partnering Conference.
The presentation will take place as follows:
- Date: Wednesday, October 4th , 2017
- Time: 4:00pm CEST
- Venue: Wyss Center in Geneva, Switzerland
If you are interested in meeting the Pharnext management team during this event, please send an email to Anne Hennecke at firstname.lastname@example.org .
Pharnext is an advanced clinical-stage biopharmaceutical company founded by renowned scientists and entrepreneurs including Professor Daniel Cohen, a pioneer in modern genomics. Pharnext has two lead products in clinical development. PXT3003 is currently in an international Phase 3 trial for the treatment of Charcot-Marie-Tooth disease type 1A and benefits from orphan drug status in Europe and the United States. PXT864 has generated positive Phase 2 results in Alzheimer’s disease. Pharnext is the pioneer of a new drug discovery paradigm: PLEOTHERAPY™. The Company identifies and develops synergic combinations of repositioned drugs at new optimal lower doses. These PLEODRUG™ offer several key advantages: efficacy, safety and intellectual property including several product or composition of matter patents already granted. The Company is supported by a world-class scientific team.
The company Pharnext is listed on Euronext Growth Stock Exchange in
Paris (ISIN code: FR00111911287).
For more information, visit www.pharnext.com
Xavier Paoli, +33 (0)1 41 09 22 30
Chief Commercial Officer
Investor Relations (Europe)
MC Services AG
Anne Hennecke, +49 211 529252 22
Investor Relations (U.S.)
Stern Investor Relations, Inc.
Matthew Shinseki, +1 212 362 1200
Financial Communication (France)
Stéphane Ruiz, +33 (0)1 56 88 11 15
Media Relations (Europe)
+33 (0)1 44 54 36 64
Media Relations (U.S.)
+1 212 223 4017
Information om Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco
Følg pressemeddelelser fra Business Wire
Skriv dig op her og modtag pressemeddelelser på mail. Indtast din mail, klik på abonner og følg instruktionerne i den udsendte mail.
Flere pressemeddelelser fra Business Wire
AZ-VERSUM-MATERIALS19.4.2018 22:17 | pressemeddelelse
Versum Materials Celebrates the Grand Opening of Its Research and Development Facility in Hometown, PA
PHARNEXT19.4.2018 17:47 | pressemeddelelse
Pharnext to Showcase PLEOTHERAPY™ R&D Platform at the 8th Annual Global Orphan Drug Conference
CA-MASIMO19.4.2018 17:03 | pressemeddelelse
New Study Investigates the Utility of Masimo SpHb® in Post-operative Red Blood Cell (RBC) Transfusion Best Practices
CA-SYNTERACT19.4.2018 16:08 | pressemeddelelse
Synteract Repositions Itself with Centers of Therapeutic Development and Unveils Updated Brand Platform
NEL-ASA19.4.2018 16:02 | pressemeddelelse
Nel ASA: Receives Additional Purchase Order from Nikola
VOITH19.4.2018 15:41 | pressemeddelelse
Voith and Franka Emika Form a Strategic Partnership
I vores nyhedsrum kan du læse alle vores pressemeddelelser, tilgå materiale i form af billeder og dokumenter, og finde vores kontaktoplysninger.Besøg vores nyhedsrum